Celtaxsys, Inc.

21 articles about Celtaxsys, Inc.

• 

  Celtaxsys’ Phase II Cystic Fibrosis Trial Fails, Despite Positive Spin

  8/3/2018

  Atlanta-based Celtaxsys reported results from its Phase II EMPIRE-CF clinical trial of acebilustat for cystic fibrosis (CF), putting a positive spin on what looks to be a failed clinical trial.

• Celtaxsys Announces the Issue of Four New Patents Expanding Its Pipeline of Selective Leukotriene B4 Modulation Anti-Inflammatory Medicines

  2/1/2018

  The new patents extend its leadership position in development of a robust pipeline of inhibitors of Leukotriene A4 Hydrolase.

• Celtaxsys Secures Private Financing to Advance Acebilustat Phase III Cystic Fibrosis (CF) Program Preparatory Activities

  1/4/2018

  In conjunction with the financing, Khalil Barrage, Managing Director at Invus, will join Celtaxsys’ board of directors.

• Celtaxsys, Inc. Begins U.S. Enrollment For Phase 2 Trial Of Acebilustat Anti-Inflammatory Therapy For Cystic Fibrosis

  10/8/2015

• Celtaxsys, Inc. Gains FDA Clearance For Landmark Phase 2 Trial Of Anti-Inflammatory Treatment For Cystic Fibrosis (CF)

  7/6/2015

• Celtaxsys, Inc. Secures $45M In Capital To Fund Novel Anti-Inflammatory Phase 2 Programs In Cystic Fibrosis And Acne

  6/8/2015

• Celtaxsys, Inc. Receives $5M Research Award To Advance Once Daily, Oral Anti-Inflammatory Medicine Into Phase 2 CF Patient Lung Function Preservation Trial

  6/2/2015

• Celtaxsys, Inc. Has Regulatory Clearance To Begin Phase 2 Trial Of Oral CTX-4430 Anti-Inflammatory Therapy For Moderate To Severe Acne Vulgaris - Recruitment Of Patients To Commence Immediately

  4/7/2015

• Celtaxsys, Inc. Lead Candidate Granted Orphan Designation In Cystic Fibrosis By FDA

  2/3/2015

• Celtaxsys, Inc. Announces Sanjeev Ahuja As Chief Medical Officer

  11/7/2014

• Celtaxsys, Inc. Initiates First Clinical Trial of Oral CTX-4430 Therapy in Cystic Fibrosis Patients

  10/11/2013

• Celtaxsys, Inc. Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430

  9/17/2013

• Celtaxsys, Inc. Restructures Management and Operations; CEO, CTO Out

  9/10/2013

• Celtaxsys, Inc. Appoints Khalil Barrage to Board of Directors

  4/19/2013

• Celtaxsys, Inc. Initiates Phase 1 Study of CTX-4430 Oral Treatment for Pulmonary Inflammation

  1/3/2013

• Brett Premack, Ph.D. Joins Celtaxsys, Inc. as Chief Technology Officer

  10/24/2012

• Celtaxsys, Inc. Acquires Clinical Stage Innate Immunity Drug for Inflammation

  1/5/2012

• Dr. H. Daniel Perez Joins Celtaxsys, Inc. Board of Directors

  6/6/2011

• Dr. Michael Hanley Joins Celtaxsys, Inc. as CEO

  12/3/2010

• Celtaxsys, Inc. Seeks $10 Million to Develop Immune System Drugs; Raises $4.2 Million So Far

  11/5/2010